First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 841 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Ending smoking could more than halve England’s cancer inequality gap September 21, 2022 Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’ March 16, 2021 UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation March 8, 2019 EU Cancer Mission and Partners Launch First Cancer Mission Forum for... December 2, 2025 Load more HOT NEWS Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended... Motixafortide May Improve Stem Cell Transplants for People with Multiple Myeloma For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored
